A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide

Cornelia Feiterna-Sperling; H Walter; V Wahn; N Kleinkauf

A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide

Eur J Med Res. 2009 Jan 28;14(1):44-6.

Authors

Cornelia Feiterna-Sperling¹, H Walter, V Wahn, N Kleinkauf

Affiliation

¹ Charité, Campus Virchow-Klinikum, Department of Pediatric Pneumology and Immunology, Augustenburger Platz 1, 13353 Berlin, Germany. [email protected]

PMID: 19258211

Abstract

For intensively pretreated pediatric patients with human immunodeficiency virus type 1 (HIV-1) infection, the treatment options available are limited. We report the case of a highly treatment-experienced 12-year-old boy with multidrug-resistant HIV-1, who was successfully treated with highly active antiretroviral therapy (HAART) including ritonavir-boosted tipranavir oral solution, a novel non-peptic protease inhibitor, and enfuvirtide.

Publication types

Case Reports

MeSH terms

Anti-HIV Agents / therapeutic use*
Antiretroviral Therapy, Highly Active / methods*
Child
Drug Resistance, Multiple, Viral / drug effects*
Drug Therapy, Combination
Enfuvirtide
HIV Envelope Protein gp41 / therapeutic use
HIV Infections / drug therapy*
HIV Infections / virology
HIV-1 / drug effects*
Humans
Male
Peptide Fragments / therapeutic use
Pyridines / therapeutic use
Pyrones / therapeutic use
Remission Induction
Ritonavir / therapeutic use
Sulfonamides
Treatment Outcome

Substances

Anti-HIV Agents
HIV Envelope Protein gp41
Peptide Fragments
Pyridines
Pyrones
Sulfonamides
Enfuvirtide
Ritonavir
tipranavir